Do walnuts lower cholesterol?

Yes, by a small and very consistent amount. The largest meta-analysis, 49 randomized trials in 4,591 adults, found walnuts lowered LDL cholesterol by 5.68 mg/dL against control diets, roughly 5.8 mg/dL (0.15 mmol/L), on evidence its authors rated moderate certainty. Total cholesterol fell 6.39 mg/dL. Two other walnut meta-analyses land within a fraction of a milligram of that. The fall is bigger when walnuts replace a typical Western diet and in people carrying extra weight. No trial has measured heart attacks or strokes.

Established. Walnuts lower LDL cholesterol. Every walnut meta-analysis of trials we found points the same way, and the 2026 synthesis rated its total cholesterol result very high certainty, with the effect holding in every subgroup it tested. The size is modest: an umbrella review of 108 systematic reviews put walnuts among foods with small to moderate LDL reductions, weaker than oats, plant sterols or canola oil.

What the trials found

The size, from four syntheses

The 2026 meta-analysis pooled 49 randomized trials of adults, healthy or at cardiometabolic risk, with walnut doses and control diets that varied and lasted from 4 days to 104 weeks. LDL fell 5.68 mg/dL, with an interval from 3.47 to 7.89. The trials disagreed with each other a good deal, and the effect still survived every subgroup and every leave-one-out test. Triglycerides fell 6.25 mg/dL and HDL did not change.

A 2022 meta-analysis of 13 randomized trials in 1,037 people found the same LDL figure, 5.68 mg/dL, with total cholesterol down 8.58 and triglycerides down 10.94 mg/dL. One of its trials used walnut leaf extract instead of nuts. A 2018 analysis of 26 trials with 1,059 people, some of them not randomized, found LDL down 5.51 mg/dL and total cholesterol down 6.99. The earliest pooling, from 2009, found 9.2 mg/dL in 13 small trials where walnuts supplied 10 to 24 percent of calories for 4 to 24 weeks. Later and larger syntheses give the smaller figure.

For context, a 2025 meta-analysis of 113 randomized trials of nuts of all kinds, at a median 45.5 g a day in 8,060 adults, found LDL down 0.12 mmol/L, roughly 4.6 mg/dL. Walnuts sit inside that range. A network analysis of 34 trials ranked walnuts second of five tree nuts for lowering total cholesterol and triglycerides, after pistachios, and its authors rated that evidence low.

The longest trial

In the Walnuts and Healthy Aging trial, 628 healthy adults aged 63 to 79 in Barcelona and Loma Linda ate 1.1 to 2.1 oz (30 to 60 g) of walnuts a day for two years, about 15 percent of their calories, or kept to a walnut-free diet. LDL fell 4.3 mg/dL, with an interval from 1.6 to 6.6, and total cholesterol fell 8.5 mg/dL. Cholesterol was a secondary outcome in that trial, whose main question was cognition, and a share of the participants, 32 percent, were already on statins. The total number of LDL particles fell 4.3 percent.

Who gains more

Against an American or Western diet, the 2018 analysis found LDL down 8.28 mg/dL. In the 2022 analysis, trials with an average BMI above 25 saw 8.28 mg/dL against 3.76 in leaner groups. Those are comparisons between trials, not tests within them. In WAHA, men saw LDL fall 7.9 percent and women 2.6 percent, a difference that reached significance. The trial reported the split by sex only in per cent, and the overall fall in mg/dL was the 4.3 above. No meta-analysis has tested the sex difference.

Much of the gain seems to come from what walnuts replace. In a controlled-feeding crossover trial of 34 adults at cardiovascular risk, every test diet cut saturated fat. The walnut diet, 57 to 99 g a day, lowered LDL 6.9 mg/dL more than a diet where oleic acid replaced the alpha-linolenic acid that walnuts supply. Against a third diet with the same fatty acids but no walnuts, the walnut diet showed no significant gain.

Unsettled. Apolipoprotein B, a count of the particles that carry cholesterol into artery walls, is where the two newest meta-analyses part ways. One, of 25 randomized trials in 2,155 people, found ApoB down 0.06 g/L. The larger 2026 analysis found no overall change and a fall only above 1.8 oz (50 g) of walnuts a day, with low certainty. Fewer trials report ApoB than LDL, which is why the question is still open.

Who should be careful

Not for everyone. If you are allergic to tree nuts, walnuts are not a cholesterol option. A systematic review of 36 prevalence studies found challenge-confirmed tree nut allergy in under 2 percent of people, with walnut among the most common tree nut allergies in the USA and the UK. Nearly all tree nuts have caused fatal reactions.

Walnuts are energy dense. A review of trials published from 2017 to 2021 found all 8 that measured blood lipids favored walnuts, and all 6 that measured body weight or composition slightly favored the control diet, with most of those effects small. That review counted results and did not pool their size. In the two-year WAHA trial, weight on 30 to 60 g a day changed by 0.13 lb (0.06 kg), against a fall of 1.1 lb (0.51 kg) in the control group. Walnuts help lipids most when they replace other foods.

If you have chronic kidney disease, the evidence is thin. One systematic review found 4 studies with 1,270 patients, in which walnuts lowered LDL without upsetting electrolytes, and all of them were at moderate to high risk of bias. Nuts are high in potassium and phosphorus, and the absence of a signal in four studies is not the same as safety. That decision belongs with a renal dietitian.

We found no evidence on walnuts alongside cholesterol-lowering medicines, nor anything specific to pregnancy or children.

What expert bodies say

The European Union refused to authorize the label claim that walnuts support cardiovascular health, and it also refused the claim that 1.1 oz (30 g) of nuts a day, walnuts included, helps maintain heart health. A refusal means the dossier did not meet the bar at assessment. It does not mean walnuts have no effect. The one walnut claim Europe has authorized is that walnuts contribute to the elasticity of blood vessels, which is a vascular measurement and says nothing about cholesterol. The umbrella review above graded the evidence that walnuts produce small to moderate LDL reductions as moderate. We found no walnut position from a US body or the WHO in our sources.

How we searched

What would change this answer

• A trial measuring heart attacks or strokes. Every number on this page is a blood marker, and the effect on events is inferred from LDL.
• More trials reporting ApoB, to settle whether walnuts lower the number of cholesterol-carrying particles or only the cholesterol inside them.
• A trial built to compare men and women. The one trial that split by sex found LDL falls of 7.9 and 2.6 percent in men and women, and nobody has repeated it.
• One registered trial comparing a walnut diet with a nut-free diet, with blood lipids as the main outcome, is active and no longer recruiting (NCT05321277).

More on the nut itself, from its fats to how it compares with other nuts, is on the walnuts page.

Sources

1. ev-walchol-01 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials with GRADE · n = 4591
   The pooled results demonstrated that walnut consumption led to a statistically significant decrease in LDL‐C levels (WMD: −5.68 mg/dL; 95% CI: −7.89 to −3.47; p < 0.001) (Figure 2C).
   
   Who: adults in 49 RCTs (19 parallel, 29 crossover), healthy or with cardiometabolic risk; walnut doses and controls varied, interventions 4 days to 104 weeks
   Effect: LDL WMD -5.68 mg/dL (95% CI -7.89 to -3.47), I2 = 85.5%; GRADE moderate for LDL
   Certainty: Largest walnut synthesis; heterogeneity high but the effect held in every subgroup and leave-one-out analysis. -5.68 mg/dL is about -0.15 mmol/L.
   Food Science & Nutrition, 2026 · checked 2026-10-07 · we read the fulltext
2. ev-walchol-02 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials with GRADE · n = 4591
   Pooled analysis revealed that walnut intake significantly reduced TC (WMD: −6.39 mg/dL; 95% CI: −8.54 to −4.23; p < 0.001) (Figure 2B).
   
   Who: adults in 49 RCTs of walnut-enriched versus control diets
   Effect: total cholesterol WMD -6.39 mg/dL (95% CI -8.54 to -4.23), I2 = 68.1%; triglycerides -6.25 mg/dL; HDL no significant change (+0.71 mg/dL, 95% CI -0.24 to 1.68)
   Certainty: Authors rated total cholesterol certainty as very high; HDL and ApoB low.
   Food Science & Nutrition, 2026 · checked 2026-10-07 · we read the fulltext
3. ev-walchol-03 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials with GRADE · n = —
   Combined data from eligible studies showed that walnut intake had no significant effect on Apo‐A1 (WMD: −0.00 g/L; 95% CI: −0.01 to 0.00; p = 0.573) (Figure 2E) or Apo‐B (WMD: 0.01 g/L; 95% CI: −0.02 to 0.05; p = 0.462) (Figure 2F).
   
   Who: adults in RCTs reporting ApoB
   Effect: ApoB WMD +0.01 g/L (95% CI -0.02 to 0.05), p = 0.462; significant ApoB fall only in the >50 g/day subgroup; GRADE low for ApoB
   Certainty: Diverges from 41858294 (ApoB fall in 25 RCTs). Fewer trials report ApoB than LDL, so the particle-number question stays open.
   Food Science & Nutrition, 2026 · checked 2026-10-07 · we read the fulltext
4. ev-walchol-04 · Randomized controlled trial(s) · systematic review and random-effects meta-analysis of controlled trials · n = 1059
   The following weighted mean differences (WMDs) in reductions were obtained for walnut-enriched diets compared with control groups: -6.99 mg/dL (95% CI: -9.39, -4.58 mg/dL; P < 0.001) (3.25% greater reduction) for total blood cholesterol (TC) and -5.51 mg/dL (95% CI: -7.72, -3.29 mg/dL; P < 0.001) (3.73% greater reduction) for low-density lipoprotein (LDL) cholesterol.
   
   Who: participants of 26 controlled trials comparing walnut-enriched with control diets
   Effect: LDL WMD -5.51 mg/dL (95% CI -7.72 to -3.29), 3.73% greater reduction; vs American/Western diets LDL -8.28 (95% CI -13.04 to -3.51); total cholesterol -6.99 mg/dL
   Certainty: Includes some non-randomized controlled trials; body weight and blood pressure did not change.
   Am J Clin Nutr, 2018 · checked 2026-10-07 · we read the abstract
5. ev-walchol-05 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of randomized controlled trials · n = 1037
   The overall effect of the weighted mean difference (WMD) showed significant reductions in TC (WMD: −8.58 mg/dL; 95% CI: −12.94, −5.21; p < 0.0001), LDL-C (WMD: −5.68 mg/dL; 95% CI: −8.13, −3.24; p < 0.0001), and TG (WMD: −10.94 mg/dL; 95% CI: −15.65, −6.23; p < 0.0001).
   
   Who: adults in 13 RCTs published since 2010, walnut doses mostly 15 to 99 g/day for 6 to 52 weeks; healthy, diabetic, overweight, hypercholesterolemic participants
   Effect: LDL WMD -5.68 mg/dL (95% CI -8.13 to -3.24); TC -8.58 mg/dL; TG -10.94 mg/dL; HDL -0.57 mg/dL (NS)
   Certainty: 515 intervention and 522 control participants; one included trial used walnut leaf extract, not nuts.
   Nutrients, 2022 · checked 2026-10-07 · we read the fulltext
6. ev-walchol-06 · Meta-analysis or systematic review · subgroup analysis within a meta-analysis of randomized controlled trials · n = 1037
   Regarding LDL-C, a much-lowering effect was observed among those with mean BMI > 25 kg/m2 compared to those with 25 kg/m2 or less (−8.28 vs. −3.76).
   
   Who: RCT subgroups by mean BMI, baseline LDL and trial duration
   Effect: LDL -8.28 (BMI > 25) vs -3.76 mg/dL (BMI <= 25); -7.43 (baseline LDL < 130) vs -4.94 mg/dL (>= 130); -6.69 (<= 12 weeks) vs -4.21 mg/dL (> 12 weeks)
   Certainty: Subgroup comparisons are observational across trials; not a test of interaction within trials.
   Nutrients, 2022 · checked 2026-10-07 · we read the fulltext
7. ev-walchol-07 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of trials · n = 365
   When compared with control diets, diets supplemented with walnuts resulted in a significantly greater decrease in total cholesterol and in LDL-cholesterol concentrations (total cholesterol: WMD = -10.3 mg/dL, P < 0.001; LDL cholesterol: WMD = -9.2 mg/dL, P < 0.001).
   
   Who: participants in 13 trials of walnut-enhanced versus control diets; walnuts 10 to 24% of energy, 4 to 24 weeks
   Effect: total cholesterol WMD -10.3 mg/dL, LDL -9.2 mg/dL (both P < 0.001); HDL and triglycerides not significantly changed
   Certainty: Small, short, high-dose trials; later and larger syntheses give a smaller effect of about 5 to 6 mg/dL.
   Am J Clin Nutr, 2009 · checked 2026-10-07 · we read the abstract
8. ev-walchol-08 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of randomized controlled trials · n = 2155
   Walnut significantly decreased ApoB (WMD = -0.06; 95% CI: -0.10, -0.01, p = 0.002), but did not affect ApoA1 (WMD = -0.50; 95% CI: -1.34, 0.33, p = 0.249), systolic blood pressure (SBP) (WMD = -1.20; 95% CI: -4.02, 1.61, p = 0.401) and diastolic blood pressure (DBP) (WMD = -0.44; 95% CI: -2.55, 1.67, p = 0.682).
   
   Who: adults in 25 RCTs (26 intervention arms) of walnut supplementation
   Effect: ApoB WMD -0.06 (95% CI -0.10 to -0.01), p = 0.002; ApoA1, SBP, DBP not significant
   Certainty: Search to January 2025; disagrees with 41676011 on ApoB overall. ApoB tracks the number of atherogenic particles.
   Endocrinol Diabetes Metab, 2026 · checked 2026-10-07 · we read the abstract
9. ev-walchol-09 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials · n = 8060
   Overall, nut consumption resulted in moderate reductions in total cholesterol (mean difference, -0.14 mmol/L [95 % confidence interval, -0.18 to -0.10 mmol/L]) and LDL-C (-0.12 mmol/L [-0.14 to -0.09 mmol/L]), with small reductions in triglycerides (-0.05 mmol/L [-0.07 to -0.03 mmol/L]), TC:HDL-C (-0.11 [-0.16 to -0.06]), LDL-C:HDL-C (-0.19 [-0.24 to -0.12]), and apolipoprotein B (-0.04 g/L [-0.06 to -0.02 g/L]).
   
   Who: adults with various health status in 113 RCTs of nuts versus non-nut control
   Effect: LDL MD -4.6 mg/dL (95% CI -5.4 to -3.5; metric: -0.12 mmol/L, -0.14 to -0.09); TC -0.14 mmol/L; TG -4.4 mg/dL (-0.05 mmol/L); ApoB -0.04 g/L; HDL unchanged; certainty mostly moderate/low
   Certainty: All nut types pooled, not walnuts alone; gives the class context for the walnut effect (about -4.6 mg/dL).
   Nutr Metab Cardiovasc Dis, 2025 · checked 2026-10-07 · we read the abstract
10. ev-walchol-10 · Meta-analysis or systematic review · network meta-analysis of randomized clinical trials · n = 1677
    For TG and TC reductions, the walnut-enriched diet was ranked as the second-best diet.
    
    Who: participants in 34 RCTs comparing walnut, pistachio, hazelnut, cashew, almond and control diets
    Effect: SUCRA ranking: pistachio first for TG, LDL, TC; walnut second for TG and TC; almond second for LDL; walnut and pistachio better than control for TG, LDL, TC
    Certainty: Rankings rest on few head-to-head trials and poor reporting; the authors rate the evidence low.
    Am J Clin Nutr, 2020 · checked 2026-10-07 · we read the abstract
11. ev-walchol-11 · Meta-analysis or systematic review · umbrella review of guidelines, systematic reviews and RCTs with GRADE · n = —
    Pulses, hazelnuts, walnuts, high-fiber/wholegrain foods, and green tea caused small to moderate reductions, whereas sugar caused a small increase.
    
    Who: adults in RCTs pooled by systematic reviews of foods and LDL cholesterol, at least 13 days
    Effect: walnuts: small to moderate LDL reduction, moderate GRADE; high-evidence moderate reductions (7.7 to 15 mg/dL (0.20 to 0.40 mmol/L)) for unsaturated oils, plant sterols/stanols, soluble fiber
    Certainty: Places walnuts among foods with real but modest LDL effects.
    Nutr Metab Cardiovasc Dis, 2021 · checked 2026-10-07 · we read the abstract
12. ev-walchol-12 · Randomized controlled trial(s) · 2-center, 2-year, parallel-group randomized controlled trial (secondary lipoprotein analysis) · n = 628
    The walnut diet significantly decreased (mg/dL) total cholesterol (mean –8.5 [95% CI, –11.2 to –5.4]), LDL-C (mean –4.3 [–6.6 to –1.6]), and intermediate-density lipoprotein cholesterol (–1.3 [–1.5 to –1.0]), corresponding to reductions of 4.4%, 3.6%, and 16.8%, respectively, whereas triglycerides and high-density lipoprotein cholesterol were unaffected (Figure, B and C).
    
    Who: cognitively healthy elders aged 63 to 79 in Barcelona and Loma Linda; walnuts about 15% of energy (30 to 60 g/d) vs walnut-free diet; mean age 69, 67% women, 32% on statins
    Effect: TC -8.5 mg/dL (95% CI -11.2 to -5.4), LDL -4.3 mg/dL (-6.6 to -1.6), IDL cholesterol -1.3 mg/dL; reductions of 4.4%, 3.6% and 16.8%; triglycerides and HDL unchanged; total LDL particles -4.3%, small LDL particles -6.1%
    Certainty: Longest and largest walnut trial; lipids were a secondary outcome (primary was cognition). Free-living, no feeding.
    Circulation, 2021 · checked 2026-10-07 · we read the fulltext
13. ev-walchol-13 · Randomized controlled trial(s) · 2-year parallel-group randomized controlled trial, prespecified subgroup by sex · n = 628
    Lipid responses to the walnut diet differed by sex: LDL-C was reduced by 7.9% in men and by 2.6% in women ( P -interaction=0.007).
    
    Who: healthy elders aged 63 to 79, 67% women, walnuts 30 to 60 g/day for 2 years
    Effect: LDL -7.9% in men vs -2.6% in women, P-interaction = 0.007; no difference by study site
    Certainty: Single trial; the sex difference has not been tested in a meta-analysis.
    Circulation, 2021 · checked 2026-10-07 · we read the fulltext
14. ev-walchol-14 · Randomized controlled trial(s) · randomized crossover controlled-feeding trial, NCT01235832 · n = 34
    Compared with the ORAD, total cholesterol (mean ± SEM -8.9± 2.3 mg/dL; -5.1%; P < 0.001), non-HDL cholesterol (-7.4 ± 2.0 mg/dL; -5.4%; P = 0.001), and LDL cholesterol (-6.9 ± 1.9 mg/dL; -6.5%; P = 0.001) were lower after the WD; no other pairwise differences existed.
    
    Who: adults at risk of cardiovascular disease, mean age 44, BMI 30.1; 6-week diet periods after a 2-week run-in
    Effect: vs oleic acid diet: TC -8.9 mg/dL (-5.1%), non-HDL -7.4 mg/dL (-5.4%), LDL -6.9 mg/dL (-6.5%); Lp(a), cholesterol efflux and PCSK9 unchanged
    Certainty: All test diets cut saturated fat; the walnut-specific edge over a fatty-acid-matched diet was not significant, so the gain is mostly from replacing saturated fat.
    J Nutr, 2020 · checked 2026-10-07 · we read the abstract
15. ev-walchol-15 · Observational data · systematic review of prevalence studies · n = —
    Prevalence of individual tree nut allergies varied significantly by region with hazelnut the most common tree nut allergy in Europe, walnut and cashew in the USA and Brazil nut, almond and walnut most commonly reported in the UK.
    
    Who: children and adults in 36 population prevalence studies, mostly European
    Effect: challenge-confirmed IgE-mediated tree nut allergy < 2%; probable 0.05 to 4.9%; walnut and cashew most common in the USA
    Certainty: Nearly all tree nuts have caused fatal reactions; people with tree nut allergy cannot use walnuts for cholesterol.
    Curr Allergy Asthma Rep, 2015 · checked 2026-10-07 · we read the abstract
16. ev-walchol-16 · Meta-analysis or systematic review · systematic review of RCTs and cohort studies with vote counting, PROSPERO registered · n = 1948
    With respect to blood lipids, results from 8/8 RCTs favoured walnuts, in accordance with associations with a reduced risk of CVD suggested by cohort studies; results from 6/6 RCTs favoured control with respect to body weight and composition, although most of these effects were small.
    
    Who: 23 RCTs (walnuts about 10 to 99 g/day, 1,948 subjects) and 10 cohort studies (about 675,928 subjects)
    Effect: blood lipids: 8/8 RCTs favored walnuts; body weight and composition: 6/6 RCTs favored control, effects mostly small
    Certainty: Vote counting, not pooled sizes; only 1 RCT at low risk of bias. Walnuts are energy dense, so they help lipids most when they replace other foods.
    Nutrition Reviews, 2022 · checked 2026-10-07 · we read the abstract
17. ev-walchol-17 · Randomized controlled trial(s) · 2-year parallel-group randomized controlled trial · n = 628
    Compliance with the walnut diet was good and body weight was stable, with mean 2-year changes of 0.06 kg (95% CI, –0.32 to 0.44) in the walnut diet and –0.51 kg (95% CI, –0.91 to –0.12) in controls.
    
    Who: healthy elders aged 63 to 79, walnuts about 15% of energy, 2 years
    Effect: 2-year weight change +0.13 lb (95% CI -0.71 to 0.97; metric: 0.06 kg, -0.32 to 0.44) walnut vs -1.1 lb (-2 to -0.26; metric: -0.51 kg, -0.91 to -0.12) control
    Certainty: Free-living older adults; a 1.3 lb (0.57 kg) gap over 2 years.
    Circulation, 2021 · checked 2026-10-07 · we read the fulltext
18. ev-walchol-18 · Position of an expert body · EU Register on nutrition and health claims, claim POL-HC-8134, snapshot of 2026-09-21 · n = —
    POL-HC-8134 Walnuts Walnuts support cardiovascular health. Non-authorised
    
    Who: foods sold in the EU
    Effect: claim status: Non-authorized
    Certainty: Non-authorized means the evidence submitted did not meet the bar at assessment, not that walnuts have no effect.
    EU Register on nutrition and health claims, claim POL-HC-8134, snapshot 2026-09-21 · checked 2026-10-07 · we read the section
19. ev-walchol-19 · Position of an expert body · EU Register on nutrition and health claims, claim POL-HC-7666, snapshot of 2026-09-21 · n = —
    POL-HC-7666 Nuts - peanuts and tree nuts (almonds, hazelnuts, pecans, pistachios and walnuts), excluding brazil, macadamia and cashew nuts Eating 30g of nuts per day as part of a balanced diet helps maintain heart health. Non-authorised
    
    Who: foods sold in the EU
    Effect: claim status: Non-authorized
    Certainty: Contrasts with the US, where FDA allowed a qualified walnut and heart disease claim in 2004 (letter not retrieved, not carded).
    EU Register on nutrition and health claims, claim POL-HC-7666, snapshot 2026-09-21 · checked 2026-10-07 · we read the section
20. wal-dr-05 · Observational data · systematic review of nut intake and lipid profile, inflammation, oxidative stress, blood pressure and mortality in chronic kidney disease, five databases searched May 2024 and again February 2025 with no restriction on date, language or study type, PROSPERO CRD42024543880 · n = 1270
    Overall the findings indicate positive effects of Brazil nuts and baru almond oil on oxidative stress and inflammation markers, while walnuts reduced LDL cholesterol and blood pressure while posing no risk regarding electrolytes balance.
    
    Who: 4 studies (three trials and one cohort) with 1270 patients with chronic kidney disease, out of 2521 records screened
    Effect: walnuts lowered LDL cholesterol and blood pressure with no risk to electrolyte balance; Brazil nuts and baru almond oil affected oxidative stress and inflammation markers; total nut consumption was associated with lower all-cause mortality
    Certainty: four studies, heterogeneous, and all at moderate to high risk of bias by the authors' own assessment. The electrolyte point is the reason this card exists: people with kidney disease are told to watch potassium and phosphorus, and nuts are high in both, so the absence of a signal in these few studies is worth knowing and is not the same as safety. This is decided with a renal dietitian, not from a food page
    Front Nutr, 2025 · checked 2026-09-22 · we read the abstract
21. wal-dr-06 · Position of an expert body · EU Register on nutrition and health claims, claim POL-HC-6525, snapshot of 2026-09-21 · n = —
    POL-HC-6525 Walnuts Walnuts contribute to the improvement of the elasticity of blood vessels Authorised
    
    Who: —
    Effect: five register entries name walnuts, of which one is Authorised and four Non-authorized; the authorized wording is that walnuts contribute to the improvement of the elasticity of blood vessels
    Certainty: an authorized claim carries a condition of use, the amount that has to be eaten, and that column is missing from this snapshot. Without it the claim tells a reader nothing actionable. Note also what it does not say: elasticity of blood vessels is a vascular measurement, not a reduction in heart attacks, and the register does not grade the strength of the evidence behind an approval
    EU Register on nutrition and health claims, claim POL-HC-6525, snapshot 2026-09-21 · checked 2026-09-22 · we read the row